Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer

Therapeutic antibodies that block the programmed cell death protein‐1 (PD‐1) immune checkpoint pathway prevent T‐cell downregulation and promote immune responses against cancer. Several PD‐1 pathway inhibitors have shown robust activity in initial trials. This article reviews the preclinical evidence, rationale, and clinical pharmacology of blockade of PD‐1 or its ligands as therapy for lung cancer and provides an overview of agents in development, clinical evidence to date, and implications for clinical application.

• Publication year

  2014

• Venue

  Clinical pharmacology and therapy

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/clpt.2014.74PMID 24690569PMCID 5685326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Non-small cell lung cancer, version 2.2013.

  2013cited by this paper
• PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

  2013cited by this paper
• Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor.

  2013cited by this paper
• Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models.

  2013cited by this paper
• Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models.

  2013cited by this paper
• Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

  2013cited by this paper
• A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

  2013cited by this paper
• A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).

  2013cited by this paper
• L02.04 AMP-224, A FUSION PROTEIN THAT TARGETS PD-1

  2013cited by this paper
• Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.

  2013cited by this paper
• Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

  2013cited by this paper
• Critical Review of Preclinical Approaches to Investigate Cytochrome P450–Mediated Therapeutic Protein Drug-Drug Interactions and Recommendations for Best Practices: A White Paper

  2013cited by this paper
• PD-1 as a potential target in cancer therapy

  2013cited by this paper
• Immunological Response as a Source to Variability in Drug Metabolism and Transport

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention

  2012cited by this paper
• State of the Science: An Update on Renal Cell Carcinoma

  2012cited by this paper
• Programmed Death Ligand 2 in Cancer-Induced Immune Suppression

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development

  2011cited by this paper
• Anti‐PD‐1 synergizes with cyclophosphamide to induce potent anti‐tumor vaccine effects through novel mechanisms

  2011cited by this paper
• PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

  2011cited by this paper
• The potential for crizotinib in non-small cell lung cancer: a perspective review

  2011cited by this paper
• CYP-Mediated Therapeutic Protein-Drug Interactions

  2010cited by this paper
• Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

  2010cited by this paper
• Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009

  2010cited by this paper
• Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy

  2010cited by this paper
• The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors

  2009cited by this paper
• PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

  2009cited by this paper
• Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.

  2009cited by this paper
• Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma

  2009cited by this paper
• The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.

  2008cited by this paper
• Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

  2008cited by this paper
• Inhibitory B7-family molecules in the tumour microenvironment

  2008cited by this paper
• Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

  2007cited by this paper
• Biochemical mechanisms of cisplatin cytotoxicity.

  2007cited by this paper
• Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

  2007cited by this paper
• Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell Vaccine1

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro

  2006cited by this paper
• Cancer despite immunosurveillance: immunoselection and immunosubversion

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

  2005cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

  2004cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

  2003cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Immunotherapy in lung cancer.

  1998cited by this paper
• Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

  year unknowncited by this paper

• A Retrospective Study of First‐Line Immunotherapy for Advanced Non‐Small Cell Lung Cancer in the Elderly

  2025cites this paper
• Immune Checkpoint Inhibitors Therapy as the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape.

  2023cites this paper
• Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience

  2023cites this paper
• Prediction of Efficacy of Immunotherapy for Extensive Stage Small Cell Lung Cancer

  2023cites this paper
• Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy

  2022cites this paper
• Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression

  2021cites this paper
• Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review

  2021cites this paper
• dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50.

  2021cites this paper
• Optimizing Survival by Changing the Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.

  2020cites this paper
• Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017).

  2020cites this paper
• Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies

  2020cites this paper
• Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.

  2020cites this paper
• Genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer identified by systems therapeutics analyses

  2019cites this paper
• Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.

  2019cites this paper
• Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression

  2019cites this paper
• Tumor-associated macrophages mediate immune suppression by secreting PD-L1+ exosomes in epithelial ovarian cancer

  2019cites this paper
• Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

  2019cites this paper
• Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

  2019cites this paper
• Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: implications for immunotherapy.

  2019cites this paper
• Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

  2018influential citation
• The Role of Cytochromes P450 in Infection

  2018cites this paper
• Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.

  2018cites this paper
• Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort

  2018cites this paper
• Systems therapeutics analyses identify genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancer

  2018cites this paper
• This information is current as Infection in Mice Clearance of Persistent Cryptococcal Lung PD-1 Antibody Treatment Promotes − Anti

  2018cites this paper
• Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy

  2018cites this paper
• Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives

  2018cites this paper
• Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort

  2018cites this paper
• Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives

  2017cites this paper
• Understanding the checkpoint blockade in lung cancer immunotherapy.

  2017cites this paper
• Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence

  2017cites this paper
• Immunotherapy Comes of Age in Lung Cancer

  2017cites this paper
• Immune checkpoint inhibitors in cancer therapy

  2017cites this paper
• Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events

  2017influential citation
• Anti–PD-1 Antibody Treatment Promotes Clearance of Persistent Cryptococcal Lung Infection in Mice

  2017cites this paper
• Current Status of Immunotherapy for Non-Small-Cell Lung Cancer

  2016cites this paper
• PD-L1 expression is associated with advanced non-small cell lung cancer

  2016cites this paper
• Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities

  2016cites this paper
• Combination of immune stimulatory strategies to promote anti-tumour immunity

  2016cites this paper
• Advances in immunotherapy for melanoma management

  2016cites this paper
• Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.

  2016cites this paper
• Enhanced therapeutic effect of an antiangiogenesis peptide on lung cancer in vivo combined with salmonella VNP20009 carrying a Sox2 shRNA construct

  2016cites this paper
• Regulation of Natural Killer Cell Function by STAT3

  2016cites this paper
• Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer

  2016cites this paper
• Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

  2016cites this paper
• DNA Repair Gene Polymorphisms in Non-Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Containing Chemotherapy

  2016cites this paper
• Intralesional and systemic immunotherapy for metastatic melanoma

  2016cites this paper
• Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model

  2016cites this paper
• Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer

  2015cites this paper
• OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal

  2015cites this paper
• Novel drug therapies in myeloid leukemia.

  2015cites this paper
• Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy

  2015cites this paper
• Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma

  2015cites this paper
• Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.

  2015cites this paper
• The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

  2015cites this paper
• The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

  2015cites this paper
• Upregulation of PD-1 on CD4⁺CD25⁺ T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis.

  2015cites this paper
• RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

  2015cites this paper
• Nivolumab in NSCLC: latest evidence and clinical potential

  2015cites this paper
• Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.

  2015cites this paper
• Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

  2015cites this paper
• Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?

  2015cites this paper
• Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model

  2015cites this paper
• Emerging Strategies for Cancer Immunoprevention

  2015cites this paper
• PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia

  2015cites this paper
• Non-small-cell lung cancer

  2015cites this paper
• From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy

  2015cites this paper
• CANCER IMMUNOLOGY AND IMMUNOTHERAPY - UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES

  2015cites this paper
• Overview of molecular-targeted drugs available in Tenri Hospital

  2015cites this paper
• Synthetic immunity to break down the bottleneck of cancer immunotherapy

  2015cites this paper
• Expression of Pd-1, Cd160 and 2b4 on Cd8 T Cells During HIV infection: Markers of Exhaustion?

  2015cites this paper
• Stem Cells of the Distal Bronchiolar Airways

  2015cites this paper
• Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.

  2015cites this paper
• Programmed death receptor PD-1 as a potential target in anticancer therapy

  2015influential citation
• Inflammation: The Dynamic Force of Health and Disease

  2014cites this paper
• Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents

  2014cites this paper
• The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy

  2014cites this paper
• Interferon-γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment

  2014cites this paper
• Current state of immunotherapy for non-small cell lung cancer.

  2007cites this paper